71 FR 231 pgs. 69589-69590 - Manufacturer of Controlled Substances; Notice of Application
Type: NOTICEVolume: 71Number: 231Pages: 69589 - 69590
FR document: [FR Doc. E6-20339 Filed 11-30-06; 8:45 am]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version: PDF Version
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 25, 2006, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:
| Drug | Schedule |
|---|---|
| N-Ethylamphetamine (1475) | I |
| 2,5-Dimethoxyamphetamine (7396) | I |
| 4-Methoxyamphetamine (7411) | I |
| Difenoxin (9168) | I |
| Dihydromorphine (9145) | I |
| Amphetamine (1100) | II |
| Methamphetamine (1105) | II |
| Methylphenidate (1724) | II |
| Pentobarbital (2270) | II |
| Secobarbital (2315) | II |
| Codeine (9050) | II |
| Dihydrocodeine (9120) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Diphenoxylate (9170) | II |
| Hydrocodone (9193) | II |
| Meperidine (9230) | II |
| Dextropropoxyphene, bulk (non-dosage forms) (9273) | II |
| Morphine (9300) | II |
| Thebaine (9333) | II |
| Opium Extracts (9610) | II |
| Opium Fluid Extract (9620) | II |
| Opium Tincture (9630) | II |
| Opium, Granulated (9640) | II |
| Oxymorphone (9652) | II |
| Noroxymorphone (9668) | II |
| Opium, Powdered (9639) | II |
| Alfentanil (9737) | II |
| Sufentanil (9740) | II |
| Fentanyl (9801) | II |
The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a).
Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway,Alexandria, Virginia 22301; and must be filed no later than January 30, 2007.
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E6-20339 Filed 11-30-06; 8:45 am]
BILLING CODE 4410-09-P